A Phase 3 interventional study of Donepezil (Aricept) and Placebo in Alzheimer Disease, sponsored by Pfizer. Completed at 53 sites in Sweden. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 7th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2002, is one of 10 in phase 3, and was the 23rd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
101 studies in Alzheimer Disease by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 99 finished, 40 (40%) have results posted.
Among the 101 studies in Alzheimer Disease by Pfizer, this one is the 15th largest by enrollment of the 94 interventional ones that give a count, is the only one that started in 2002, is one of 14 in phase 3, and was the 34th registered.
Pfizer’s Alzheimer Disease studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 101 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of Aricept in nursing home patients with severe Alzheimer's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Donepezil (Aricept)
Drug: Placebo
Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
Matching placebo tablets orally once daily for 6 months
Change from baseline in modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-severe) total score
Time frame: Month 6
Change from baseline in Severe Impairment Battery (SIB) total score
Time frame: Month 6
Change from baseline in SIB total score
Time frame: Month 3
Change from baseline in Neuropsychiatric Inventory (NPI) total score
Time frame: Months 3 and 6
Change from inclusion in Mini Mental State Examination (MMSE) total score
Time frame: Month 6
Change from baseline in Clinical Global Impression of Improvement (CGI-I) score
Time frame: Months 3 and 6
Adverse events and laboratory value changes
Time frame: Months 3 and 6
Change from baseline in modified ADCS-ADL-severe total score
Time frame: Month 3
The record gives a start of Oct 2002 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil